Bladder Cancer Coverage from Every Angle

Wesley Yip, MD, on Clinical Implications of New Findings on Neoadjuvant Chemotherapy for Urothelial Carcinoma

Posted: Wednesday, March 16, 2022

Wesley Yip, MD, of Memorial Sloan Kettering Cancer Center, discusses new trial results suggesting a benefit to neoadjuvant gemcitabine and cisplatin given prior to nephroureterectomy for patients with high-grade upper tract urothelial carcinoma, and what that could mean for clinical practice.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.